查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1793682

全球甲沟炎治疗市场

Paronychia Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 371 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计2030年全球甲沟炎治疗市场规模将达7.018亿美元

全球甲沟炎治疗市场规模预计在2024年为5.18亿美元，预计在分析期内（2024-2030年）将以5.2%的复合年增长率增长，到2030年将达到7.018亿美元。急性子宫内膜异位症是本报告分析的细分市场之一，预计其复合年增长率为4.3%，到分析期结束时将达到4.619亿美元。慢性甲沟炎细分市场在分析期间的复合年增长率预计为7.0%。

美国市场规模估计为 1.411 亿美元，中国市场预计复合年增长率为 8.1%

美国甲沟炎治疗市场规模预计2024年达到1.411亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到1.387亿美元，在2024-2030年的分析期内，复合年增长率为8.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为2.6%和5.1%。在欧洲，预计德国市场的复合年增长率为3.3%。

全球甲沟炎治疗市场－主要趋势与驱动因素摘要

人们越来越关注有效的甲沟炎治疗策略是什么？

甲沟炎是一种影响手指甲和脚趾甲周围皮肤的发炎性疾病，由于其急性和慢性发病率高，已引起越来越多的临床关注。甲沟炎通常由轻微创伤或长期暴露于潮湿环境中的细菌、真菌或混合感染引起，可导致严重不适、功能受限，有时甚至形成脓肿。糖尿病、免疫抑製或职业性刺激物暴露患者的发病率不断上升，这促使人们对准确诊断和及时治疗的需求日益增加。

治疗方法因类型和严重程度而异。急性病例通常以局部或口服抗生素治疗，并根据需要进行引流；慢性病例通常采用抗真菌治疗和行为矫正，以尽量减少接触刺激物。针对性治疗、更快速的症状缓解和预防復发的需求，促使人们采用门诊联合治疗、抗菌方案和微创手术。

治疗方案如何演变以应对急性疾病和慢性疾病？

对于急性细菌性甲沟炎，通常使用头孢氨芐、克林霉素和阿莫西林-克拉维酸钾等口服抗生素，尤其是在有蜂窝组织炎的情况下。如果脓液储存，则在无菌条件下切开患处并引流。对于局部、轻度病例，也可使用具有抗发炎特性的外用抗生素。

慢性甲沟炎的治疗已转向抗真菌药物（尤其是Azole或Terbinafine）合併皮质类固醇的抗发炎治疗。医生会开立隔离霜和润肤剂来恢復皮肤完整性，并保护其免受水分和刺激物的进一步侵害。復发性或疗效较差的病例需要手术治疗，例如副甲状腺切除术或部分甲剥离术。治疗方法越来越个人化，取决于微生物培养结果、合併症以及病人对预防保健的依从性。

甲沟炎治疗的需求将会在哪里成长，哪些患者族群将受到最大影响？

基层医疗和皮肤科诊所的需求都在增长，尤其是在都市区和职业健康领域。医护人员、食品处理人员、游泳者以及洗手习惯不良的人属于高危险群。患有异位性皮肤炎、糖尿病和接受免疫抑制治疗的患者更容易患上慢性皮肤炎。有咬指甲和吸吮拇指习惯的儿科患者数量也在增加。

在亚太和拉丁美洲等新兴市场，由于人们意识的提高和皮肤病护理可近性的提高，诊断和治疗的数量正在增加。在已开发地区，人口老化和糖尿病盛行率的上升也促进了临床需求的稳定。药房和远端医疗平台在提供治疗可及性方面也发挥着越来越重要的作用，尤其是对于透过局部用药和卫生教育进行治疗的轻度和復发性病例。

甲沟炎治疗市场的成长受到多种因素的推动。

甲沟炎治疗感染疾病的成长受到许多因素的推动，例如细菌性和真菌性甲癣盛行率的上升、职业和生活方式相关风​​险因素的增加，以及人们对皮肤健康的认识不断提高。糖尿病患者人数的增加、皮肤敏感的老年人以及免疫力缺乏的患者群体不断壮大，需要进行急性和长期治疗。

局部治疗、抗生素-抗真菌联合製剂以及微创引流技术的进步改善了临床疗效，并降低了復发率。基层医疗转向早期诊断和自我护理，以及远端医疗咨询的增多，正在推动治疗的发展。抗真菌药物供应的增加、新兴经济体皮肤科服务可及性的提高以及手部和指甲卫生教育的普及，也支持了市场的持续扩张。

部分

类型（急性指甲、慢性指甲）、药物类型（莫匹罗星软膏、夫西地酸软膏、庆大霉素软膏、双氯西林）、最终用户（医院/诊所、皮肤病中心）

受访公司范例

  • AbbVie Inc.
  • Allergen Plc（Allergan）
  • Bayer AG
  • BioNTech SE
  • ConvaTec Group Plc
  • Eli Lilly and Company
  • Fougera Pharmaceuticals Inc.
  • Galderma SA
  • Glenmark Generics Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Jonakayem Pharma Formulation Pvt. Ltd.
  • Merck & Co., Inc.
  • Mundipharma（with Moberg Pharma alliance）
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Perrigo New York, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Taro Pharmaceutical Industries Ltd.

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP37660

Global Paronychia Treatment Market to Reach US$701.8 Million by 2030

The global market for Paronychia Treatment estimated at US$518.0 Million in the year 2024, is expected to reach US$701.8 Million by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Acute Paronychia, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$461.9 Million by the end of the analysis period. Growth in the Chronic Paronychia segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$141.1 Million While China is Forecast to Grow at 8.1% CAGR

The Paronychia Treatment market in the U.S. is estimated at US$141.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$138.7 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Paronychia Treatment Market - Key Trends & Drivers Summarized

What Is Prompting Greater Focus on Effective Paronychia Management Strategies?

Paronychia, an inflammatory condition affecting the skin around the fingernails or toenails, is receiving increasing clinical attention due to its high prevalence across both acute and chronic forms. Commonly caused by bacterial, fungal, or mixed infections following minor trauma or prolonged moisture exposure, paronychia can lead to significant discomfort, functional limitation, and in some cases, abscess formation. The growing incidence among individuals with diabetes, immunosuppression, or occupational exposure to irritants is intensifying demand for accurate diagnosis and timely treatment.

Treatment approaches differ based on the type and severity. Acute cases are often treated with topical or oral antibiotics and drainage when necessary, while chronic paronychia typically involves antifungal therapies and behavioral modifications to minimize exposure to irritants. The need for targeted therapy, faster symptom relief, and recurrence prevention is supporting adoption of combination therapies, antiseptic regimens, and minimally invasive procedures in outpatient settings.

How Are Therapeutic Options Evolving to Address Both Acute and Chronic Forms?

For acute bacterial paronychia, oral antibiotics such as cephalexin, clindamycin, or amoxicillin-clavulanate are commonly used, especially when cellulitis is present. In cases where pus accumulation occurs, incision and drainage are performed under sterile conditions. Topical antibiotic formulations with anti-inflammatory properties are also used for localized, mild presentations.

Chronic paronychia management has shifted toward antifungal treatments, particularly topical azoles or terbinafine, combined with corticosteroids to reduce inflammation. Barrier creams and emollients are prescribed to restore skin integrity and protect against recurrent exposure to moisture and irritants. In recurrent or unresponsive cases, surgical interventions like eponychial marsupialization or partial nail avulsion may be required. Treatment regimens are increasingly personalized based on microbiological cultures, comorbid conditions, and patient adherence to preventive care.

Where Is Demand for Paronychia Treatment Growing and Which Patient Segments Are Most Affected?

Demand is growing in both primary care and dermatology clinics, particularly in urban and occupational health settings. Healthcare workers, food handlers, swimmers, and individuals with repeated hand-washing routines are at higher risk. Chronic cases are more common in those with atopic dermatitis, diabetes, or individuals on immunosuppressive therapy. Pediatric cases are also rising due to nail-biting and finger-sucking habits.

Emerging markets in Asia-Pacific and Latin America are seeing increased diagnosis and treatment as awareness improves and access to dermatological care expands. In developed regions, the aging population and higher rates of diabetes contribute to steady clinical demand. Pharmacies and telemedicine platforms are also playing a growing role in treatment access, especially for mild or recurrent cases managed with topical agents and hygiene education.

Growth in the Paronychia Treatment market is driven by several factors…

Growth in the paronychia treatment market is driven by factors such as rising prevalence of bacterial and fungal nail infections, increased exposure to occupational and lifestyle-related risk factors, and expanding awareness of dermatological health. The growing diabetic population, aging individuals with fragile skin, and immunocompromised patients contribute to a sustained patient base requiring both acute and long-term management.

Advancements in topical therapies, antibiotic-antifungal combination products, and minimally invasive drainage techniques are improving clinical outcomes and reducing recurrence. The shift toward early diagnosis and self-care in primary care settings, along with rising telehealth consultations, is increasing treatment initiation. Improved availability of antifungal agents, growing access to dermatological services in emerging economies, and wider education on hand and nail hygiene are also supporting consistent market expansion.

SCOPE OF STUDY:

The report analyzes the Paronychia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Acute Paronychia, Chronic Paronychia); Drug Type (Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment, Dicloxacillin); End-Use (Hospitals & Clinics End-Use, Dermatology Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Allergen Plc (Allergan)
  • Bayer AG
  • BioNTech SE
  • ConvaTec Group Plc
  • Eli Lilly and Company
  • Fougera Pharmaceuticals Inc.
  • Galderma S.A.
  • Glenmark Generics Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Jonakayem Pharma Formulation Pvt. Ltd.
  • Merck & Co., Inc.
  • Mundipharma (with Moberg Pharma alliance)
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Perrigo New York, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Taro Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Paronychia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Nail Infections and Skin Disorders Spurs Demand for Effective Paronychia Treatment Options
    • Increasing Awareness of Hand and Foot Hygiene Strengthens Market for Topical and Oral Antimicrobial Therapies
    • Growing Prevalence of Chronic Conditions Such as Diabetes Throws the Spotlight on Recurrent and Complicated Paronychia Cases
    • Expansion of Dermatology Clinics and Telehealth Services Improves Access to Early Diagnosis and Prescription Treatments
    • Advancements in Antifungal and Antibacterial Drug Formulations Enhance Efficacy in Treating Both Acute and Chronic Cases
    • Rising Demand for Combination Therapies Supports the Use of Dual-Action Antibiotic and Antifungal Medications
    • Growth in At-Home Treatment Products and Over-the-Counter Creams Fuels Self-Management Among Consumers
    • Increasing Focus on Cosmetic Nail Health and Grooming Drives Demand for Preventive Treatment and Care Products
    • Surgical and Drainage Procedures for Abscess Management Expand Market for Post-Procedure Wound Care Solutions
    • Product Innovation in Moisturizing and Healing Ointments Enhances User Compliance and Recovery Outcomes
    • Rising Incidence of Occupational Nail Injuries Among Healthcare, Salon, and Construction Workers Drives Targeted Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Paronychia Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Paronychia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Paronychia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Paronychia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mupirocin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mupirocin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Mupirocin Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fusidic Acid Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fusidic Acid Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Fusidic Acid Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gentamicin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gentamicin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Gentamicin Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dicloxacillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dicloxacillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Dicloxacillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Dermatology Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Dermatology Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Dermatology Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Paronychia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Paronychia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Paronychia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Paronychia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION